Full Press Release Details
SAN DIEGO, March 27, 2020 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of shareholders of AnaptysBio, Inc. ("AnaptysBio" or the Company") (NASDAQ: ANAB). The class action is on behalf of shareholders who purchased AnaptysBio common stock between October 10, 2017 and November 7, 2019, inclusive (the "Class Period"). If you wish to serve as lead plaintiff in this class action, you must move the Court no later than May 26, 2020.
[Click here to join this action]
The lawsuit alleges that AnaptysBio made misrepresentations regarding the efficacy of etokimab, a drug for inflammatory diseases. During the Class Period, the lawsuit claims that AnaptysBio provided misleading clinical trial data, which failed to disclose vital information and used questionable analysis, making the trial results regarding etokimab's efficacy and its prospects appear far better than they were.
If you are interested in learning more about the case, please contact Jim Baker (jimb@johnsonfistel.com) at 619-814-4471. If you email, please include your phone number.
Additionally, you can [Click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Jim Baker, 619-814-4471